ESMO 2024 | Challenges in liquid biopsy implementation for metastatic cancer

Michail Ignatiadis • 14 Sep 2024

ESMO 2024

Breast Cancer

Michail Ignatiadis, MD, PhD, Jules Bordet Institute, Brussels, Belgium, gives an overview of key challenges in integrating liquid biopsy in the metastatic setting, including educating clinicians, establishing workflows for implementing these assays in clinical practice, and setting up molecular tumor boards to interpret results. Additionally, financial aspects, including reimbursement for these assays as companion diagnostics, remain a significant hurdle in widespread adoption. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.